Table 4.
Summary of the clinical data of patients with and without hs-TnT rise
| Variable | hs-TnT rise (n = 28) | hs-TnT non-rise (n = 17) | p-value |
|---|---|---|---|
| • Patient’s characteristics | |||
| Male gender, n (%) | 22 (78.6) | 14 (82.3) | 1.0000 |
| Age, years (mean ± SD) | 71.40 ± 9.24 | 65.35 ± 14.64 | 0.1400 |
| • Associated diseases/risk factors | |||
| Coronary artery disease | 17 (60.7) | 11 (64.7) | 1.0000 |
| Smoking, n (%) | 3 (10.7) | 2 (11.8) | 1.0000 |
| Hypertension | 18 (64.3) | 10 (58.8) | 0.7591 |
| Diabetes, n (%) | 7 (25.0) | 7 (41.2) | 0.3262 |
| Chronic renal failure, n (%) | 1 (3.6) | 1 (5.9) | 1.0000 |
| COPD, n (%) | 2 (7.1) | 1 (5.9) | 1.0000 |
| BMI (mean ± SD) | 29.55 ± 5.70 | 27.93 ± 5.91 | 0.5209 |
| • Dental procedure-related variables | |||
| Number of extracted teeth (mean ± SD) | 2.25 ± 1.38 | 2±1.37 | 0.5575 |
| Flap opened, n (%) | 13 (46.4) | 5 (29.4) | 0.3513 |
| Bone removal, n (%) | 7 (25.0) | 4 (23.5) | 1.0000 |
| Numberof LA carpules (mean ± SD) | 2.36 ± 0.9 | 2.09 ± 0.78 | 0.2935 |
| Oral sedation (20 mg of diazepam), n (%) | 7 (25.0) | 7 (41.2) | 0.3262 |
| Preoperative GTN, n (%) | 1 (3.6) | 0 (0.0) | 1.0000 |
| Antibiotic cover, n (%) | 5 (17.6) | 1 (5.9) | 0.3846 |
| • Medications | |||
| Single antiplatelets, n (%) | 14 (50.0) | 8 (47.1) | 1.0000 |
| Dual antiplatelets, n (%) | 1 (3.6) | 2 (11.8) | 0.5471 |
| Beta-blockers, n (%) | 16 (57.1) | 8 (47.1) | 0.5521 |
| Statins, n (%) | 17 (60.7) | 9 (52.9) | 0.5754 |
| Ezetimibe, n (%) | 2 (7.1) | 3 (17.7) | 0.3590 |
| Warfarin, n (%) | 10 (35.7) | 2 (11.8) | 0.0962 |
| ACE inhibitors, n (%) | 15 (53.6) | 8 (47.1) | 0.7631 |
| Calcium-channel blockers, n (%) | 5 (17.6) | 4 (23.5) | 0.7109 |
| Nitrates, n (%) | 4 (14.3) | 1 (5.9) | 0.6343 |
| Cardiac glycosides, n (%) | 2 (7.1) | 2 (11.8) | 0.6262 |
| Proton-pump inhibitors, n (%) | 2 (7.1) | 5 (29.4) | 0.0858 |
| Diuretics, n (%) | 12 (42.9) | 4 (23.5) | 0.2187 |
| ARBs, n (%) | 2 (7.1) | 1 (5.9) | 1.0000 |
| Oral hypoglycemics, n (%) | 4 (14.3) | 6 (35.3) | 0.1434 |
| Insulin, n (%) | 1 (3.6) | 0 (0.0) | 1.0000 |
| Seretide inhaler, n (%) | 1 (3.6) | 1 (5.9) | 1.0000 |
| Anticholinergics, n (%) | 2 (7.1) | 1 (5.9) | 1.0000 |
| Beta-2 agonists, n (%) | 3 (10.7) | 2 (11.8) | 1.0000 |
| Antiepileptics, n (%) | 1 (3.6) | 2 (11.8) | 0.5471 |
| Antidepressants, n (%) | 3 (10.7) | 2 (11.8) | 1.0000 |
ACE inhibitors angiotensin-converting enzyme inhibitors, ARBS angiotensin receptor blockers, BMI body mass index, COPD chronic obstructive pulmonary disease, GTN glyceryl trinitrate, LA local anesthetic